Why did IPN.PA stock jump on 13 Feb 2026?

The jump followed FY 2025 results and management guidance for >13.00% sales growth in 2026, upgraded margin targets, pipeline milestones and acquisition news. Strong volume (146,747) signalled conviction among investors.

What is Ipsen’s valuation and financial health for IPN.PA stock?

Ipsen trades at PE **27.49** with EPS **€5.37**, market cap ~**€12.21bn**, free cash flow per share **€9.76**, and debt-to-equity **0.23**, indicating a conservative balance sheet and healthy cash generation.

What are the main risks for IPN.PA stock investors?

Main risks include negative clinical readouts, competitive generic pressure on Somatuline long-term, currency headwinds, and potential setbacks from late-stage business-development assumptions.

How does Meyka AI view IPN.PA stock outlook?

Meyka AI grades IPN.PA **B+ (77.61/100)** with a BUY suggestion, citing strong results, pipeline catalysts and sound fundamentals, balanced by clinical and competitive risks and a model-based one-year forecast of **€118.68**.

EU Stocks

IPN.PA Ipsen S.A. (EURONEXT) up 11.46% on 13 Feb 2026: guidance lifts outlook

ByHuzaifa Zahoor February 14, 2026February 14, 2026

IPN.PA stock climbed 11.46% to €154.70 at market close on 13 Feb 2026 after Ipsen S.A. reported strong 2025 results and issued FY 2026 guidance above expectations. Trading volume jumped to 146,747 shares, roughly 2.50x the average, as investors priced in faster portfolio growth and Somatuline supply dynamics. We examine the drivers, valuation, technicals and model forecasts that explain today’s top-gainer move on EURONEXT in the Europe healthcare patch.